中药姜黄的抗肿瘤作用

目的 :观察中药姜黄的抗肿瘤作用。方法 :采用口服灌胃对小鼠S180 肉瘤实体型、腹水型进行抑瘤实验。结果 :小鼠S180 肉瘤实体型实验组动物肿瘤明显缩小 ,在姜黄剂量为 6 0g·kg-1时 ,抑瘤率为 4 3.0 5 % ;能显著延长小鼠S180 肉瘤腹水型实验组小鼠生存期 ,在剂量为 30g·kg-1时 ,生命延长率达 81.5 1%。结论 :中药姜黄具有抗肿瘤作用。     

银耳孢糖对荷瘤小鼠环磷酰胺化疗的增效作用

目的:研究银耳孢糖(Tremella fuciformis spores polysaccharide,TSP)对环磷酰胺(CTX)化疗H22及S180荷瘤小鼠的增效作用.方法:建立小鼠肝癌H22及小鼠肉瘤S180的体内移植性肿瘤模型,随机分为对照组,TSP小、中、大剂量组,CTX小、大剂量组,TSP(小、中、大剂量) CTX小剂量组,TSP(小、中、大剂量) CTX大剂量组等12组,接种肿瘤次日开始每天分别腹腔给予0.9%氯化钠注射液、TSP(25,50及100 mg·kg-1)、CTX(10,20 mg·kg-1)、TSP(25,50,100 mg·kg-1) CTX 10 mg·kg-1及TSP(25,50及100 mg·kg-1) CTX 20 mg·kg-1,连续12～14 d,称小鼠的瘤重,测定TSP对CTX的增效作用,每批实验重复3次.结果:TSP 25,50,100 mg·kg-1可明显增加CTX(10,20 mg·kg-1)对H22及S180荷瘤小鼠的抑制作用,抑瘤率分别提高6.82～92.01%,3.90～24.27%(P<0.05,0.01);9.50～87.04%,2.41～21.51%(P<0.05,0.01).结论:TSP与CTX合用对抑制荷瘤小鼠H22及S180有明显的增效作用.     

新一代胸苷酸合成酶抑制剂ZD1694的体内外抗肿瘤作用

目的:观察ZD1694对小鼠体内S180肉瘤生长的抑制作用及其在体外对人胃腺癌SGC-7901细胞增殖的影响.方法:采用荷瘤小鼠模型,腹腔注射不同剂量的ZD1694,分单次给药与连续 5 d 分次给药两种方案.处死动物后称取肿瘤组织重量,计算抑瘤率.另外采用MTT比色法及流式细胞仪观察ZD1694对人SGC-7901胃腺癌细胞株生长的影响.结果:ZD1694可抑制小鼠体内S180肉瘤的生长,其抑瘤率无论是单次给药组(200、100、50 mg·kg-1)还是连续 5 d 给药组(40、20、10 mg·kg-1·d-1),均可见剂量依赖性增加.ZD1694(0.001～1 000 mmol·L-1)对SGC-7901人胃腺癌细胞的生长抑制率呈浓度依赖性和时间依赖性增加,可使G0-G1期细胞增多, S期和G2-M期细胞减少.结论:ZD1694对荷瘤小鼠产生明显的抗瘤作用,一次性给药的抑瘤率大于相同剂量分5次给药的抑瘤率.该药在体外可抑制人胃腺癌SGC-7901细胞生长,使细胞发生G1期阻滞.     

胡桃楸提取物的抗肿瘤作用

目的探讨胡桃楸提取物SH体内外抗肿瘤活性。方法体外实验应用MTT法检测SH对人宫颈癌细胞株HeLa、小鼠腹水型肝癌细胞株Hca-F的增殖抑制作用;体内实验应用小鼠S180实体瘤动物模型,通过对荷瘤小鼠体质量以及抑瘤率的影响,评价SH不同剂量(4.5、9.0、18.0 mg·kg-1)以及与化疗药物环磷酰胺(cyclophosphamide,CTX)联合用药对S180肉瘤的生长抑制作用。结果体外实验表明,SH可以显著抑制HeLa、Hca-F肿瘤细胞的增殖;体内实验表明,SH具有明显的抑瘤作用,中、高剂量组(9、18 mg·kg-1)的抑瘤率分别为25.9%和35.3%,与CTX联合用药时,能够提高CTX的抑瘤率,中、高剂量组(9+10 mg·kg-1、18+10 mg·kg-1)抑瘤作用呈现相加作用。结论胡桃楸提取物SH,在体外能够明显抑制HeLa、Hca-F肿瘤细胞的增殖,在体内能够抑制荷瘤小鼠S180肉瘤生长,提示胡桃楸提取物SH具有一定的抗肿瘤活性。     

青蒿素抗肿瘤作用的初步研究

目的 研究菊科植物黄花蒿的单体青蒿素(Artimisinine, ART)的抗肿瘤作用.方法 采用动物移植性肿瘤实验方法.结果 50 mg·kg-1 ART对小鼠移植性肉瘤S180的抑瘤率为37.88%;100 mg·kg-1 ART对小鼠移植性肝癌Heps实体瘤的抑瘤率为35.23%;ART对艾氏腹水癌EAC小鼠生命延长率无统计学意义.结论 ART具有良好的抗肿瘤作用.     

灵芝孢子多糖抗移植性肿瘤实验研究

目的研究灵芝孢子多糖的抗癌作用。方法采用小鼠抗移植性肿瘤实验方法。结果灵芝孢子多糖分别以150 mg.kg-13、00 mg.kg-1和600 mg.kg-1剂量连续12天灌胃给药,对小鼠移植性肝癌Heps的抑瘤率为53.77%~65.25%;连续8天灌胃给药,对小鼠移植性肉瘤S180的抑瘤率为50.39%~55.04%,皆呈良好的抑瘤作用。灵芝孢子多糖可分别提高Heps和S180荷瘤小鼠的脾指数和胸腺指数。结论灵芝孢子多糖有良好的抑瘤作用,并可增强Heps和S180荷瘤小鼠的非特异性免疫功能。     

银耳孢糖合用氟尿嘧啶对肉瘤S180和肝癌H22小鼠的抗肿瘤作用

目的对银耳孢糖与氟尿嘧啶(5-FU)合用的抗肿瘤作用进行研究.方法采用小鼠肉瘤S180和肝癌H22肿瘤模型,连续给药7 d后,剥出瘤块、胸腺及脾脏称取质量,计算抑瘤率和免疫器官指数;采用碳粒廓清实验测定吞噬指数.结果银耳孢糖合用5-FU(5,10,20 mg·kg-1)对小鼠肉瘤S180和肝癌H22有明显的抑制作用,对肉瘤S180的抑瘤率分别为41.7%,50.1%,68.8%,对肝癌H22的抑瘤率分别为42.3%,58.4%,69.8%.银耳孢糖合用5-FU能增加H22肝癌小鼠的免疫器官指数和吞噬指数.结论银耳孢糖与5-FU合用抗肿瘤具有增效作用,银耳孢糖对5-FU所致的免疫功能损伤有保护作用.     

龙须菜多糖抑瘤活性及对荷瘤小鼠抗氧化作用的研究

目的 探讨龙须菜多糖(PGL)抗肿瘤作用及对荷瘤小鼠抗氧化能力的影响.方法 以S180荷瘤小鼠为模型,研究龙须莱热水提取的多糖对S180肉瘤生长的影响,通过测定S180荷瘤小鼠血液红细胞中超氧化物歧化酶(SOD)活性和肝匀浆中脂质过氧化物(LPO)含量评价PGL对小鼠抗氧化能力的作用.结果 PGL可显著抑制小鼠S180肉瘤的生长,当灌胃剂量为150mg·kg-1时,抑瘤率达63.56%,并能明显降低荷瘤小鼠体内LPO含量.结论 PGL能提高荷瘤小鼠抗氧化能力,PGL具有的抗氧化作用可能是实现其抗肿瘤活性的机制之一.     

榄香烯哌嗪对荷瘤小鼠免疫功能的影响

目的研究榄香烯哌嗪的抗肿瘤作用及其对免疫功能的影响。方法采用小鼠S180肉瘤移植性肿瘤动物模型,以抑瘤率为指标考察榄香烯哌嗪的体内抗肿瘤活性。并用四氮唑盐(MTT)法对荷瘤小鼠进行脾淋巴细胞增殖能力和自然杀伤(NK)细胞活性测定,考察其对荷瘤小鼠免疫功能的影响。结果榄香烯哌嗪对小鼠肉瘤S180的生长有明显的抑制作用(P<0.01),502、5 mg.kg-1剂量组抑瘤率分别为48.74%和37.60%。榄香烯哌嗪各种剂量对荷瘤小鼠的胸腺指数和脾指数无明显影响,但榄香烯哌嗪剂量为502、5 mg.kg-1可显著提高荷瘤小鼠脾淋巴细胞的增殖能力,对荷瘤小鼠NK细胞活性也有明显的提高作用。结论榄香烯哌嗪具有一定的抗肿瘤作用,其抗肿瘤作用可能与激活体内免疫系统有关。     

扇贝糖蛋白及多糖对S180荷瘤小鼠的抑瘤作用

目的:研究扇贝糖蛋白及扇贝多糖对S180小鼠的抑瘤作用。方法:给小鼠接种S180腹水瘤,用不同剂量扇贝糖蛋白及扇贝多糖治疗,观察瘤重及脾脏重量。结果:40 mg·kg-1扇贝糖蛋白对S180小鼠抑瘤率为47．29％,20 mg·kg-1扇贝多糖抑瘤率为46．97％;扇贝多糖还可明显增加小鼠脾脏重量。结论:扇贝糖蛋白及扇贝多糖抑瘤效果显著,扇贝多糖还具增强免疫功能作用。     

银耳孢子多糖体内抑制肿瘤作用的研究

目的：研究银耳孢子多糖对小鼠U14宫颈癌、H22肝癌、S180肉瘤的抑制作用。方法：采用肿瘤抑制率评价银耳孢子多糖在1、6和12mg／kg3个剂量时，对肿瘤的抑制作用。结果：银耳孢子多糖在3个剂量下，对小鼠U14宫颈癌、H22肝癌、S180肉瘤均有一定的抑制作用。对于U14官颈癌，在1mg／kg剂量时，间隔给药抑瘤效果最明显，抑瘤率为43．6％，与对照组相比差异显著；对于H22肝癌，在6mg／kg剂量时，间隔给药抑瘤效果最明显，抑瘤率为72．3％，与对照组相比差异显著；对于S180肉瘤，在6mg／kg剂量时，间隔给药抑瘤效果最明显，抑瘤率为84．9％，与对照组相比差异显著。结论：银耳孢子多糖对小鼠U14宫颈癌、H22肝癌和S180肉瘤，均有较好的抑制作用。     

A novel human tumor necrosis factor alpha mutant showed potent antitumor activity and reduced toxicity in vivo.

AIM: To study the antitumor activity and systemic toxicity of human tumor necrosis factor alpha (hTNFalpha) mutant M2 (R2K-N30S-R32W-L157F-hTNFalpha). METHODS: Mouse sarcoma S180 tumors and hepatoma HAC tumors were implanted into mice, and human urocyst carcinoma CP-3 tumors were implanted into nude mice. The xenografted mice were injected with wild-type hTNFalpha and its mutant M2 at different doses. After 7 d (mice) or 10 d (nude mice) of injection, the tumor weight was measured to calculate the inhibition rate of hTNFalpha and M2. Systemic toxicity experiments were done on Rhesus monkeys by injecting them with wild-type hTNFalpha and mutant M2 respectively for 10 consecutive d. Observations were made on the monkeys both before and after the injection. RESULTS: For mice implanted with sarcoma S180 and hepatoma HAC tumors, the inhibition rate of M2 was similar to that of wild-type hTNFalpha at the dose of 0.025 mg/kg, while for nude mice implanted with human urocyst carcinoma CP-3, the inhibition rate of M2 (45.5 %) was much higher than that of wild-type hTNFalpha (15.5 %). When the dose came to 0.25 and 2.5 mg/kg respectively, however, the inhibition rate of M2 greatly increased (the highest was 75.9 %). The tests of systemic toxicity of hTNFalpha and its mutant M2 in monkeys proved that M2 presented lower toxicity than wild-type hTNFalpha did. CONCLUSION: hTNFalpha mutant M2 not only presented higher antitumor activity than wild-type hTNFalpha did on mouse tumor (S180 and HAC)- and human tumor (CP-3)-implanted mice, but also showed lower systemic toxicity in the Rhesus monkey.     

抗癌药物新剂型-多相脂质体的研究(Ⅰ)多相脂质体139等抗癌活性的筛选

<正> 一、前言脂质体(Liposomes)是将药物包封于类脂质双分子层形成的薄膜中间所成的超微型球状体。在脂质体理论研究的基础上,1971年英国Ryman等人开始将脂质体作为药物载体加以研究,近年来脂质体广泛的用作抗癌药物的载体,它具备一些独特的作用特点:如使药物具有药理活性的专一性,选择性地杀伤癌细胞或抑制癌细胞的繁殖;降低药物对正常细胞的毒性,减少剂量,减轻变态或免疫反应;增加药物对淋巴系统的指     

Immunomodulation and antitumor activity by a polysaccharide-protein complex from Lycium barbarum

The modulation of a polysaccharide-protein complex from Lycium barbarum (LBP3p) on the immune system in S180-bearing mice was investigated. The mice inoculated with S180 cell suspension were treated p.o. with LBP3p (5, 10 and 20 mg/kg) for 10 days. The effects of LBP3p on transplantable tumors and macrophage phagocytosis, quantitative hemolysis of sheep red blood cells (QHS), lymphocyte proliferation, the activity of cytotoxic T lymphocyte (CTL), interleukin-2 (IL-2) gene expression and lipid peroxidation were studied. LBP3p could significantly inhibit the growth of transplantable sarcoma S180 and increase macrophage phagocytosis, the form of antibody secreted by spleen cells, spleen lymphocyte proliferation, CTL activity, IL-2 mRNA expression level and reduce the lipid peroxidation in S180-bearing mice. The effect is not dose-dependent in a linear fashion. A total of 10 mg/kg dose is more effective than 5 and 20 mg/kg doses. This suggests that LBP3p at 10 mg/kg has a highly significant effect on tumor weight and improves the immune system.     

硫酸壳聚糖体内抗肿瘤作用的实验研究

目的：研究硫酸壳聚糖的体内抗肿瘤作用。方法：用高、低（200、100mg/kg）两个剂量的硫酸壳聚糖分别腹腔注射治疗肉瘤180（S180）小鼠和艾氏腹水癌（EAC）小鼠10d,然后测定其抑瘤率、重要器官的内脏指数和生命延长率,同时设生理盐水组（空白对照组）和氟尿嘧啶组（阳性对照组）进行比较。结果：硫酸壳聚糖高、低剂量组和氟尿嘧啶组的抑瘤率分别为38.67%、30.19%和43.27%,3组的生命延长率分别为65.38%、69.23%和54.93%。和生理盐水组、氟尿嘧啶组相比,硫酸壳聚糖高、低剂量组的S180小鼠的胸腺指数均有明显增加（P〈0.05）。结论：硫酸壳聚糖能有效抑制S180小鼠肿瘤的生长和延长EAC小鼠的生存时间,其作用机制可能与其提高机体的免疫力有关。     

蟾蜍毒素对S180小鼠移植瘤的抑制作用及其毒副作用的实验研究

目的探讨醇溶性蟾蜍毒素在小鼠体内对S180肿瘤细胞的抑制作用及其毒副作用。方法本研究用乙醇溶解蟾蜍分泌物原浆,采用减压蒸馏等方法进一步部分分离纯化,获得醇溶性的蟾蜍毒素混合物(ethanol extract of toad venom,EET),将其作用于S180荷瘤小鼠模型,计算肿瘤抑制率和生命延长率,同时通过血生化和病理等检测观察其对各脏器的毒副作用。结果5mg/kg和0·5mg/kg的EET对S180荷瘤小鼠实体瘤组织的抑瘤率分别是47·0%和34·1%(P<0·05);对腹水瘤小鼠的生命延长率分别是46·2%和36·5%(P<0·05);同时,0·5mg/kg的EET可明显升高白细胞达(11±4)×109/L(P<0·05)。但EET在5mg/kg时可引起总胆红素升高达(30±5)μmol/L(P<0·05)。结论0·5~5mg/kg的EET可以明显抑制荷瘤小鼠体内S180肿瘤细胞的生长,但EET的剂量达到5mg/kg时可以损伤肝脏。     

双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤活性及生物分布研究(英文)

近年来脂质纳米粒由于其优越的特征备受青睐。本文通过腹腔注射评价了双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤作用, 以及在荷S180昆明鼠内的生物分布研究。结果表明双氢青蒿素纳米结构脂质载体显著抑制了肿瘤的增长, 通过腹腔给药在20, 40和80mg/kg时肿瘤抑制率分别为71.24%, 79.20%和85.74%, 在荷S180小鼠体内静脉注射双氢青蒿素纳米结构脂质载体后, 药物的生物分布表明双氢青蒿素纳米结构脂质载体与双氢青蒿素溶液相比, 双氢青蒿素纳米结构脂质载体显示了明显不同的生物分布。因此, 本文实验结果确实证明了双氢青蒿素纳米结构脂质载体与双氢青蒿素普通混悬液相比, 在相同剂量下双氢青蒿素纳米结构脂质载体显示出更优越的抗肿瘤作用和剂量依赖性。     

昂立品山抑瘤口服液抗小鼠肿瘤实验研究

目的：评价昂立品山抑瘤口服液对小鼠H22肝癌和S180肉瘤的抑瘤作用。方法：小鼠预先给予昂立品山抑瘤口服液每天10，20，30ml/kg，连用21天，然后皮下接种肿瘤，继续给予口服液7天。疗效评价采用瘤体称重法。结果：昂立品山抑瘤口服液能够明显抑制以上肿瘤的生长，它对小鼠H22肝癌和S180肉瘤的抑制率分别达到41％和44％（30ml/kg)，并增加小鼠体重。结论：在本试验条件下，昂立品山抑瘤口服液能够明显抑制小鼠H22肝癌和S180肉瘤的生长，改善小鼠的营养状态。     

抗肿瘤抗生素1588的研究——Ⅲ.对动物移植性肿瘤实验治疗研究

本文报告抗生素1588对多种移植性动物肿瘤的实验治疗研究。结果表明抗生素1588按12.5 mg/kg连续给药10天,对小鼠S-180、U-14、Lio-1和B₂₂等实体癌均有明显的抑制作用。并能延长E_c、ARS,HCA等腹水癌小鼠及Walker-256(腹水型)大鼠的生命时间。但对小鼠白血病L₆₁₅无效。此外还报告了不同给药方案对S-180抑制作用的影响。本文还研究了抗生素1588的二个主要组分即1588-74-3及1588-74-9对小鼠S-180的抗肿瘤作用,并与争光霉素和平阳霉素进行了比较。     

The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo

The anticancer effects of wogonin on murine sarcoma S180 both in vitro and in vivo were investigated, and its pro-apoptotic molecular mechanism was further studied. Wogonin treatment resulted in significant inhibition of S180 cells in a concentration-dependent manner detected by MTT assay. The IC(50) value for 48 h was (7.37+/-1.53)x10(-5) M. Typical morphological changes and apoptosis bleb phenomenon in S180 cells exposed to wogonin were distinctly observed by the inverted light microscope and the fluorescence microscope, respectively. According to protocols of transplanted tumor research,(1)) mice were transplanted with tumor cells S180. The weight of tumor and the peripheral leucocyte count were observed after the treatment of wogonin. The significant suppression of tumor growth was observed, and the peripheral leucocyte count of S180-bearing mice remained no significant changes compared with control group. After the treatment of 40 mg/kg wogonin, the inhibitory rate of tumor weight was 53.01%. Additional DNA fragmentation assay showed that wogonin induced apoptosis on murine sarcoma S180 tissue. RT-PCR results indicated that the increasing mRNA levels of bax and p53 and the decreasing mRNA level of bcl-2 were induced by wogonin. Western-blot assay showed that the increasing protein level of bax and the decreasing protein level of bcl-2 were induced by wogonin. Collectively, wogonin could induce apoptosis in murine sarcoma S180 thereby inhibiting the tumor growth both in vitro and in vivo. The pro-apoptotic effects might be related to the improvement of mRNA level of p53, the improvement of mRNA and protein levels of bax, and the reduction of mRNA and protein levels of bcl-2.